NovoCure Phase 3 Glioblastoma Trial Misses Overall Survival Endpoint

MT Newswires Live06-18

NovoCure (NVCR) said Thursday a phase 3 trial evaluating its tumor treating fields therapy in patients with newly diagnosed glioblastoma failed to meet its primary endpoint.

The company said initiating TTFields therapy at the start of chemoradiation did not result in a statistically significant improvement in overall survival compared with starting the therapy during the maintenance phase.

In the intent-to-treat population, median overall survival was 17.7 months in the early-start arm, compared with 17.5 months in the maintenance-start arm, NovoCure said.

The company added that long-term survival rates were similar between the two groups, with three-year survival rates being 22.5% in the early-start arm and 18.4% in the maintenance-start arm.

Shares of the company were down more than 21% in Thursday's premarket trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2644700092?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-18 19:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2644700092","market":"us","top_or_hot":-1,"title":"NovoCure Phase 3 Glioblastoma Trial Misses Overall Survival Endpoint","media":"MT Newswires Live","content":"<html><body><p> NovoCure (NVCR) said Thursday a phase 3 trial evaluating its tumor treating fields therapy in patients with newly diagnosed glioblastoma failed to meet its primary endpoint.</p><p>The company said initiating TTFields therapy at the start of chemoradiation did not result in a statistically significant improvement in overall survival compared with starting the therapy during the maintenance phase.</p><p>In the intent-to-treat population, median overall survival was 17.7 months in the early-start arm, compared with 17.5 months in the maintenance-start arm, NovoCure said.</p><p>The company added that long-term survival rates were similar between the two groups, with three-year survival rates being 22.5% in the early-start arm and 18.4% in the maintenance-start arm.</p><p>Shares of the company were down more than 21% in Thursday's premarket trading.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NovoCure Phase 3 Glioblastoma Trial Misses Overall Survival Endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovoCure Phase 3 Glioblastoma Trial Misses Overall Survival Endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-18 19:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> NovoCure (NVCR) said Thursday a phase 3 trial evaluating its tumor treating fields therapy in patients with newly diagnosed glioblastoma failed to meet its primary endpoint.</p><p>The company said initiating TTFields therapy at the start of chemoradiation did not result in a statistically significant improvement in overall survival compared with starting the therapy during the maintenance phase.</p><p>In the intent-to-treat population, median overall survival was 17.7 months in the early-start arm, compared with 17.5 months in the maintenance-start arm, NovoCure said.</p><p>The company added that long-term survival rates were similar between the two groups, with three-year survival rates being 22.5% in the early-start arm and 18.4% in the maintenance-start arm.</p><p>Shares of the company were down more than 21% in Thursday's premarket trading.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2644700092","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2644700092","pubTimestamp":1781781872,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"NovoCure  said Thursday a phase 3 trial evaluating its tumor treating fields therapy in patients with newly diagnosed glioblastoma failed to meet its primary endpoint.The company said initiating TTFields therapy at the start of chemoradiation did not result in a statistically significant improvement in overall survival compared with starting the therapy during the maintenance phase.In the intent-to-treat population, median overall survival was 17.7 months in the early-start arm, compared with 17.5 months in the maintenance-start arm, NovoCure said.The company added that long-term survival rates were similar between the two groups, with three-year survival rates being 22.5% in the early-start arm and 18.4% in the maintenance-start arm.Shares of the company were down more than 21% in Thursday's premarket trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","NVCR":"NovoCure Limited","BK4585":"ETF&股票定投概念","BK4548":"巴美列捷福持仓","BK4534":"瑞士信贷持仓","BK4082":"医疗保健设备"},"translate_title":"Novocure 3期胶质母细胞瘤试验未达到总生存期终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVCR":1.5},"content_text":"NovoCure (NVCR) said Thursday a phase 3 trial evaluating its tumor treating fields therapy in patients with newly diagnosed glioblastoma failed to meet its primary endpoint.The company said initiating TTFields therapy at the start of chemoradiation did not result in a statistically significant improvement in overall survival compared with starting the therapy during the maintenance phase.In the intent-to-treat population, median overall survival was 17.7 months in the early-start arm, compared with 17.5 months in the maintenance-start arm, NovoCure said.The company added that long-term survival rates were similar between the two groups, with three-year survival rates being 22.5% in the early-start arm and 18.4% in the maintenance-start arm.Shares of the company were down more than 21% in Thursday's premarket trading.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2644700092","isCrawlerRequest":true}